ArticleScientific reports2026
Dihydroartemisinin exerts antitumour activity by blocking SIRT2-IGFBP1-induced PI3K/AKT/mTOR signal transduction in liver cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The human NAD (+)-dependent deacetylase silent information regulator isoform 2 (SIRT2) is the cytoplasm-localized member of the sirtuin family, which has received increasing attention for its potential roles in cancer diagnosis and therapy. However, its role is still under debate, and its molecular mechanism remains unclarified. In this study, we thoroughly investigated the function and regulatory mechanism of SIRT2 in the tumorigenesis of liver cancer and found that SIRT2 is highly expressed in liver cancer tissues and is distributed mainly in the cytoplasm of liver cancer cells. The SIRT2 expression level is positively related to cell proliferation in vitro and tumour growth in vivo. We found that SIRT2 can upregulate IGFBP1 expression and subsequently activate the PI3K/AKT/mTOR signalling pathway and that IGFBP1 is essential for the tumour-promoting function of SIRT2 in liver cancer. Moreover, we characterized that dihydroartemisinin, one of the main active metabolites of artemisinin derivatives can inhibit liver cancer cell proliferation and liver tumour growth by promoting ubiquitin-dependent SIRT2 degradation and subsequently blocking SIRT2-IGFBP1-induced PI3K/AKT/mTOR signal pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.